Company news

Eli Lilly and Company news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

June 26, 2026

Lilly launches "The Memory Radio Station" across Europe, inviting the public to visually reconstruct fading memories through GenAI

June 26, 2026

NYSE Content Update: Abridge Partners with Eli Lilly, Nvidia to Improve Healthcare

June 24, 2026

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

June 24, 2026

ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options

June 23, 2026

Lilly declares third-quarter 2026 dividend

June 22, 2026

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

June 19, 2026

4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain

June 16, 2026

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

June 14, 2026

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

June 13, 2026

Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable

June 10, 2026

Eli Lilly Canada welcomes Québec public reimbursement of Verzenio® (abemaciclib) for mBC following successful pcpa negotiation

June 10, 2026

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

June 9, 2026

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

June 8, 2026

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

June 7, 2026

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

June 6, 2026

Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

June 3, 2026

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

June 2, 2026

Camurus announces expansion of Lilly collaboration

June 1, 2026

Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas

June 1, 2026

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

May 31, 2026

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

May 28, 2026

AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine

May 28, 2026

Foundayo and Zepbound now covered for millions of Americans

May 28, 2026

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026

Lilly announces three acquisitions to build infectious disease portfolio

May 26, 2026

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

May 25, 2026

Foundayo (orforglipron), a once-daily pill taken without food or water restrictions, was associated with reduced body weight by up to 13% in adults 65 and older with obesity or overweight, in new analysis of ATTAIN-1/2

May 22, 2026

Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting

May 21, 2026

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

May 21, 2026

Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines

May 20, 2026

Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault

May 20, 2026

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference

May 18, 2026

Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth

May 16, 2026

GLP-1 Receptor Agonist Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | Eli Lilly and Company, Sanofi

May 14, 2026

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials

May 12, 2026

In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries

May 12, 2026

NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation

May 11, 2026

Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor

May 8, 2026

Prescryptive Helps Power LillyDirect®, Supporting Direct-to-Patient Access

May 6, 2026

Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

May 6, 2026

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

May 5, 2026

Lilly declares second-quarter 2026 dividend

May 4, 2026

Trulicity Market Size to Reach USD 15.30 Billion by 2035 with Strong Demand for Metabolic Treatments | SNS Insider

May 4, 2026

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

April 30, 2026

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

April 29, 2026

Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine

April 28, 2026

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera

April 27, 2026

Spherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment

April 24, 2026

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

April 20, 2026

← Newer news releases · Older news releases →

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 32 decks. Every deck is listed under its year.